Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Cellzome builds scientific advisory board with experts in proteomics, epigenetics and immunology


Heidelberg, Germany, Cambridge, UK 23rd February 2011 – Cellzome announces the appointment of four new members to its Scientific Advisory Board (SAB), further extending its scientific network in immunology, epigenetics and proteomics.

Joining the team are Professors Ruedi Aebersold; Anne Ferguson-Smith; Jeannie Lee and Diane Mathis. The announcement follows the appointment of Prof. Tony Kouzarides and Dr. Peter Machin in October last year.

David Simmons, CSO of Cellzome and chairman of the SAB said, “We are delighted to have been able to bring together the top scientists from the different disciplines on our SAB. This network of excellence will further stimulate our science and drug discovery programmes.”

Prof. Ruedi Aebersold is a pioneer in the field of proteomics. He developed a series of methods that have found wide application in this field, including methods to enable reliable protein quantification by mass spectrometry. He served as faculty member of the Universities of Washington and British Columbia and in 2000 co-founded the Institute for Systems Biology in Seattle. Most recently, he co-founded the Institute of Molecular Systems Biology at the ETH in Zurich where he is a full professor.

Prof. Anne Ferguson-Smith has established an international reputation for her work integrating the epigenetic control of genome function with developmental and physiological processes relevant to health and disease. She has more than two decades of experience in the exploration of links between gene regulation, large and small non-coding RNAs and epigenetic modifications, and the consequences of perturbations in these interactions for pre and postnatal well-being. She is Professor of Developmental Genetics at the University of Cambridge and contributes to a range of national and international review panels and initiatives at the interface of genomic and epigenomics research.

Prof. Jeannie Lee is an Investigator of the Howard Hughes Medical Institute and Professor of Genetics (and Pathology) at Harvard Medical School and the Massachusetts General Hospital. Since she became independent in 1997, her lab's interests have included X-inactivation, imprinting, the emerging link between noncoding RNA and chromatin control, and the evolutionary history of sex chromosomes and dosage compensation.

Prof. Diane Mathis is a Professor of Pathology at Harvard Medical School, a Principal Faculty member of the Harvard Stem Cell Institute and an Associate Member at the Broad Institute. Her laboratory works in the fields of T-cell differentia tion and autoimmunity, with a special emphasis on exploiting the most advanced transgenic and gene-targeting technologies.

The four distinguished scientists join Professors Christopher Buckley, Sir Philip Cohen, Tony Kouzarides, David Sabatini, Giulio Superti-Furga, Arthur Weiss and Dr. Peter Machin on the Cellzome SAB, representing a global network of scientific excellence.

For full biographies of the Cellzome SAB please see: www.cellzome.com/sab.html

- ends -


For more information please contact:

Cellzome:

Tim Edwards

Chief Executive Officer
Tel: +49 (0) 6221-137 57-100
press@cellzome.com

Media contact:

Nicole Yost, Jayne Crook

College Hill

Tel: +44 (0)20 7866 7862

cellzome@collegehill.com

About Cellzome

Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology. The Company maintains the highest levels of scientific expertise and has active collaborations with the foremost academic laboratories around the world. Cellzome’s technologies work with native proteins in a physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases. The Company has a track record in delivering significant collaborations with top pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis. Cellzome is a privately-held, international, company located in Heidelberg, Germany and Cambridge, UK employing about 100 people. For more information please visit: www.cellzome.com


Publisher Contact Information:

Cellzome AG
+49 (0) 6221-137 57-100
press@cellzome.com

Company profile of Cellzome (acquired by GlaxoSmithKline)
Past press releases of Cellzome (acquired by GlaxoSmithKline).

Data


26,837
Tech investments
From our Online Data Service
17,319
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Apr 2€6.0MOther Computers & Electronics
Apr 2€50.0MBiotechnology
Apr 2€0.7MMedical devices
Apr 2€0.9MWireless applications
Apr 2€100.0MContent management
Apr 1€416.0MOther Biotechnology & Healthcare

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.